Hypothalamic dysfunction and neuroendocrine research in Parkinson’s disease

  • K.-P. Lesch
Part of the Key Topics in Brain Research book series (KEYTOPICS)


The progress of discovery and the expansion of the principal science base of neuroendocrinology to comprise neural science as well as endocrinology include the role of neurotransmitters in the control of hypophysiotropic neurons, the concept of neurosecretion, and the chemical structures of hypothalamic releasing and inhibiting hormones. These advances have corresponded with the emergence of neurobiology of the CNS, with the understanding of the neuropeptides, and some comprehension of their relevance to brain function, their involvement in neuropsychiatric disorders including Parkinson’s Disease (PD) and depression, and their introduction into diagnostic strategies and monitoring of treatment.


Growth Hormone Release Dexamethasone Suppression Test Inhibit Growth Hormone Release Paradoxical Growth Hormone Cortisol Nonsuppression 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Beckmann H, Lesch KP (1989) Neurochemische Untersuchungen in der Psychiatrie. In: Kisker KP, et al (Hrsg) Psychiatrie der Gegenwart, Bd IX. Springer, Berlin Heidelberg New York Tokyo (im Druck)Google Scholar
  2. Birkmayer W, Riederer P (1985) Die Parkinson-Krankheit. Biochemie, Klink, Therapie, 2. Aufl. Springer, Wien New YorkGoogle Scholar
  3. Conte-Devolx B, Grino M, Nieoullon A, Javoy-Agid F, Castanas E, Guillaume V, Tonon MC, Vaudry H, Oliver C (1985) Corticotropin, somatocrinin and amine contents in normal and parkinsonian human hypothalamus. Neuroscience Lett 56: 217–222CrossRefGoogle Scholar
  4. Eisler T, Thorner MO, MacLeod RM, Kaiser DL, Calne DB (1981) Prolactin secretion in Parkinson disease. Neurology 31: 1356–1359PubMedGoogle Scholar
  5. Fuchs G, Maurer K, Kuhn W, Przuntek H (1987) Depression bei Morbus Parkinson. In: Beckmann H, Laux G (Hrsg) Biologische Psychiatrie. Springer, Berlin Heidelberg New York Tokyo, S 185–187Google Scholar
  6. Malarkey WB, Cyrus J, Paulson GW (1974) Dissociation of growth hormone and prolactin secretion in Parkinson’s disease following chronic L-dopa therapy. J Clin Endocrinol Metab 39: 229–235PubMedCrossRefGoogle Scholar
  7. Martinez-Campos A, Giovannini P, Cocchi D, Zanardi P, Parati EA, Caraceni T, Müller EE (1981) Growth hormone secretion in neurological disorder. In: Martin JB, Reichlin S, Bick KL (eds) Neurosecretion and brain peptides. Raven, New York, pp 521–540Google Scholar
  8. Mayeux R, Stern Y, Williams JBW, Cote L, Frantz A, Dyrenfurth I (1986) Clinical and biochemical features of depression in Parkinson’s disease. Am J Psychiatr 143: 756–759PubMedGoogle Scholar
  9. Laihinen A, Rinne UK (1986) Function of dopamine receptors in Parkinson’s disease: prolactin responses. Neurology 36: 393–395PubMedGoogle Scholar
  10. Laihinen A, Rinne UK (1986) Function of dopamine receptors in Parkinson’s disease: prolactin responses. Neurology 36: 393–395PubMedGoogle Scholar
  11. Lesch KP, Rupprecht R (1989) Psychoneuroendocrine research in depression: hormonal responses to releasing hormones as a probe for hypothalamic-pituitary-endorgan dysfunction. J Neural Transm (in press)Google Scholar
  12. Parkes JD, Debono AG, Marsden CD (1976) Growth hormone response in Parkinson’s disease. Lancet 12: 483–484CrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1989

Authors and Affiliations

  • K.-P. Lesch
    • 1
  1. 1.Department of PsychiatryUniversity of WürzburgWürzburgFederal Republic of Germany

Personalised recommendations